Enterprise Value
43.11M
Cash
135.8K
Avg Qtr Burn
-949.9K
Short % of Float
0.04%
Insider Ownership
15.92%
Institutional Own.
0.00%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INT230-6 Details Sarcoma | Phase 3 Initiation | |
INT230-6 Details Breast cancer | Phase 2/3 Initiation | |
INT230-6 w/ Keytruda Details Colorectal cancer , Pancreatic cancer | Phase 2 Data readout | |
INT230-6 Details Breast cancer | Phase 2 Update | |
INT230-6 w/ Yervoy Details Breast cancer, Liver cancer, Sarcoma | Phase 2 Update |